Fig. 9

Synergistic anticancer effects of TIR@siRNA mediated SDT combined ^DPPA-1 peptide mediated anti-PD-L1 therapy in CT26-bearing mice. A Therapeutic schedule for subcutaneous and intestinal in situ CT26-tumor bearing mice. B The photos of implantation of metastatic CT26 colorectal tumor. C Tumor growth curves of subcutaneous CT26 tumors during various treatments of normal saline, ^DPPA-1 peptide, TIR@siRNA with US laser irradiation and TIR@siRNA with US laser irradiation plus ^DPPA-1 peptide. D Photos of the mice at the end of various treatments (the red circles indicate the subcutaneous CT26 tumors). E Photos of the intestines dissected from the mice at the end of various treatments (the red arrows indicate the metastatic nodules of CT26 tumors). F The counting analysis of metastatic nodules in intestines. Fluorescence images G and corresponding semi quantitative analysis H of subcutaneous tumor sections with immune-fluorescence staining of CD4 and CD8 at 4 d post treatments. Fluorescence images I and corresponding semi quantitative analysis (J) of spleen sections with immunofluorescence staining of CD4 and CD8 at the end of treatments. K Flow cytometry analysis of CD44 and CD62L expression on splenic T lymphocytes at the end of the treatments. In the experiment, the dosages of IR780, Nrf2-siRNA and ^DPPA-1 were 2.0 mg/kg, 0.5 mg/kg and 30 mg/kg, respectively. All data are presented as the mean± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.005 as compared to the control, ^#P <0.05, ^##P <0.01 for the comparison between two treatment groups